RU2011152516A - Производные 2-карбоксамид-7-пиперазинил-бензофурана 774 - Google Patents
Производные 2-карбоксамид-7-пиперазинил-бензофурана 774 Download PDFInfo
- Publication number
- RU2011152516A RU2011152516A RU2011152516/04A RU2011152516A RU2011152516A RU 2011152516 A RU2011152516 A RU 2011152516A RU 2011152516/04 A RU2011152516/04 A RU 2011152516/04A RU 2011152516 A RU2011152516 A RU 2011152516A RU 2011152516 A RU2011152516 A RU 2011152516A
- Authority
- RU
- Russia
- Prior art keywords
- dementia
- alkyl
- disease
- 6alkyl
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract 17
- 229910052736 halogen Inorganic materials 0.000 claims abstract 8
- 150000002367 halogens Chemical class 0.000 claims abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 6
- 125000001424 substituent group Chemical group 0.000 claims abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 4
- -1 C1-6alkylheteroaryl Chemical group 0.000 claims abstract 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims abstract 4
- 125000004122 cyclic group Chemical group 0.000 claims abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 4
- 239000001257 hydrogen Substances 0.000 claims abstract 4
- MKTRMPIBOZYXTR-UHFFFAOYSA-N n,n-dimethyl-7-[4-(2-pyridin-2-ylethyl)piperazin-1-yl]-1-benzofuran-2-carboxamide Chemical compound C=12OC(C(=O)N(C)C)=CC2=CC=CC=1N(CC1)CCN1CCC1=CC=CC=N1 MKTRMPIBOZYXTR-UHFFFAOYSA-N 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000003118 aryl group Chemical group 0.000 claims abstract 2
- 125000004429 atom Chemical group 0.000 claims abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 2
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 206010012289 Dementia Diseases 0.000 claims 11
- 208000024827 Alzheimer disease Diseases 0.000 claims 9
- 208000020925 Bipolar disease Diseases 0.000 claims 6
- 208000010877 cognitive disease Diseases 0.000 claims 6
- 208000024714 major depressive disease Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 201000004810 Vascular dementia Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 208000024777 Prion disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 208000025307 bipolar depression Diseases 0.000 claims 2
- 230000007278 cognition impairment Effects 0.000 claims 2
- 230000003930 cognitive ability Effects 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000006641 stabilisation Effects 0.000 claims 2
- 238000011105 stabilization Methods 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000006888 Agnosia Diseases 0.000 claims 1
- 241001047040 Agnosia Species 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 206010002942 Apathy Diseases 0.000 claims 1
- 206010003062 Apraxia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000027205 Congenital disease Diseases 0.000 claims 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 102100038076 DNA dC->dU-editing enzyme APOBEC-3G Human genes 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 101000742736 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3G Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 208000017004 dementia pugilistica Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22165709P | 2009-06-30 | 2009-06-30 | |
| US61/221,657 | 2009-06-30 | ||
| PCT/SE2010/050747 WO2011002405A1 (en) | 2009-06-30 | 2010-06-29 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011152516A true RU2011152516A (ru) | 2013-08-10 |
Family
ID=43381415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011152516/04A RU2011152516A (ru) | 2009-06-30 | 2010-06-29 | Производные 2-карбоксамид-7-пиперазинил-бензофурана 774 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8367676B2 (https=) |
| EP (1) | EP2448934B1 (https=) |
| JP (1) | JP5767211B2 (https=) |
| KR (1) | KR20120110000A (https=) |
| CN (1) | CN102482264B (https=) |
| AR (1) | AR077301A1 (https=) |
| AU (1) | AU2010266753B2 (https=) |
| BR (1) | BRPI1014222A2 (https=) |
| CA (1) | CA2765475A1 (https=) |
| MX (1) | MX2011013449A (https=) |
| RU (1) | RU2011152516A (https=) |
| TW (1) | TW201103922A (https=) |
| UY (1) | UY32744A (https=) |
| WO (1) | WO2011002405A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367676B2 (en) | 2009-06-30 | 2013-02-05 | Astrazeneca Ab | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 |
| CA2821480A1 (en) | 2010-12-20 | 2012-06-28 | Astrazeneca Ab | 2-carboxamide-4-piperazinyl-benzofuran derivative |
| CN102993186B (zh) * | 2012-12-20 | 2015-11-18 | 北京海步国际医药科技发展有限公司 | 一种新型的哌嗪衍生物 |
| CN105339371A (zh) * | 2013-03-07 | 2016-02-17 | 葛兰素史密斯克莱有限责任公司 | 作为沉默调节蛋白调节剂的噻吩并[3,2-d]嘧啶-6-甲酰胺和类似物 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US12304897B2 (en) * | 2019-01-31 | 2025-05-20 | Kyorin Pharmaceutical Co., Ltd. | 15-PGDH inhibitors |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
| EP4165045A4 (en) * | 2020-06-05 | 2024-07-03 | Monash University | DOUBLE KINASE-BROMODOMAIN INHIBITORS |
| EP4213832A4 (en) * | 2020-09-18 | 2024-10-16 | Merck Sharp & Dohme LLC | Modified benzofuran-carboxamides as glucosylceramide synthase inhibitors |
| CN117430574B (zh) * | 2023-12-20 | 2024-03-22 | 潍坊医学院 | 一种苯并呋喃衍生物及其制备方法、用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9125900D0 (en) * | 1991-12-05 | 1992-02-05 | Wyeth John & Brother Ltd | Piperazine derivatives |
| DK148392D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
| CZ295937B6 (cs) | 1997-07-25 | 2005-12-14 | H. Lundbeck A/S | Indolové nebo 2,3-dihydroindolové deriváty |
| AR022303A1 (es) | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
| DE60212841T2 (de) | 2001-06-15 | 2007-06-21 | F. Hoffmann-La Roche Ag | 4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor |
| CN1675204A (zh) | 2002-06-10 | 2005-09-28 | 拜耳医药保健股份公司 | 2－杂芳基甲酰胺 |
| GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| DE10259244A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | N-(Indolethyl-)cycloamin-Verbindungen |
| DE10326939A1 (de) * | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
| DE10326940A1 (de) | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
| WO2005077885A1 (en) | 2004-02-06 | 2005-08-25 | Yale University | Ruthenium-catalyzed hydroamination of olefins |
| WO2006062481A1 (en) | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
| WO2007053093A1 (en) | 2005-11-04 | 2007-05-10 | Astrazeneca Ab | Chroman compounds as 5 ht1b antagonists |
| AR059356A1 (es) | 2006-02-14 | 2008-03-26 | Astrazeneca Ab | Nuevos radioligandos |
| JP2010504367A (ja) | 2006-09-26 | 2010-02-12 | グラクソ グループ リミテッド | 性機能障害、認知障害、精神病性障害、不安、鬱病などを処置するための５ｈｔ１ａ受容体モジュレーターとしての５−｛２−［４−（２−メチル−５−キノリニル）−ｌ−ピペリジニル］エチル｝キノリノン誘導体 |
| WO2008055808A1 (en) | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Indole and benzofuran 2-carboxamide derivatives |
| US8367676B2 (en) | 2009-06-30 | 2013-02-05 | Astrazeneca Ab | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 |
-
2010
- 2010-06-28 US US12/824,567 patent/US8367676B2/en not_active Expired - Fee Related
- 2010-06-29 AU AU2010266753A patent/AU2010266753B2/en not_active Ceased
- 2010-06-29 EP EP10794458.9A patent/EP2448934B1/en active Active
- 2010-06-29 BR BRPI1014222A patent/BRPI1014222A2/pt not_active IP Right Cessation
- 2010-06-29 JP JP2012518512A patent/JP5767211B2/ja not_active Expired - Fee Related
- 2010-06-29 UY UY0001032744A patent/UY32744A/es unknown
- 2010-06-29 WO PCT/SE2010/050747 patent/WO2011002405A1/en not_active Ceased
- 2010-06-29 MX MX2011013449A patent/MX2011013449A/es active IP Right Grant
- 2010-06-29 TW TW099121305A patent/TW201103922A/zh unknown
- 2010-06-29 CN CN201080038560.6A patent/CN102482264B/zh not_active Expired - Fee Related
- 2010-06-29 RU RU2011152516/04A patent/RU2011152516A/ru not_active Application Discontinuation
- 2010-06-29 CA CA2765475A patent/CA2765475A1/en not_active Abandoned
- 2010-06-29 KR KR1020117031427A patent/KR20120110000A/ko not_active Withdrawn
- 2010-06-30 AR ARP100102339A patent/AR077301A1/es unknown
-
2013
- 2013-02-04 US US13/758,098 patent/US8859534B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5767211B2 (ja) | 2015-08-19 |
| MX2011013449A (es) | 2012-02-13 |
| CA2765475A1 (en) | 2011-01-06 |
| TW201103922A (en) | 2011-02-01 |
| US8859534B2 (en) | 2014-10-14 |
| KR20120110000A (ko) | 2012-10-09 |
| EP2448934A4 (en) | 2012-12-05 |
| AU2010266753B2 (en) | 2013-08-08 |
| US20130296296A1 (en) | 2013-11-07 |
| UY32744A (es) | 2011-01-31 |
| JP2012532125A (ja) | 2012-12-13 |
| BRPI1014222A2 (pt) | 2017-05-16 |
| CN102482264B (zh) | 2015-10-07 |
| EP2448934B1 (en) | 2014-05-21 |
| WO2011002405A1 (en) | 2011-01-06 |
| CN102482264A (zh) | 2012-05-30 |
| EP2448934A1 (en) | 2012-05-09 |
| AU2010266753A1 (en) | 2012-01-19 |
| US20100331341A1 (en) | 2010-12-30 |
| AR077301A1 (es) | 2011-08-17 |
| US8367676B2 (en) | 2013-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011152516A (ru) | Производные 2-карбоксамид-7-пиперазинил-бензофурана 774 | |
| JP2012532125A5 (https=) | ||
| RU2011140238A (ru) | Имидазол-замещенные пиримидины, полезные в лечении заболеваний, ассоциированных с киназой-3 гликогенсинтазы, таких как болезнь альцгеймера | |
| JP2019510006A5 (https=) | ||
| JP2019506430A5 (https=) | ||
| NZ788543A (en) | Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy | |
| EA201370184A1 (ru) | Гетероарильные производные | |
| EP2813498B1 (en) | Compounds for Alzheimer's disease | |
| RU2008148902A (ru) | Производные имидазол-пиримидина для лечения заболеваний, связанных с киназой гликогенсинтазы 3 (gsk3) | |
| EA201400552A1 (ru) | Производные n-(ариламино)сульфонамидов, включая полиморфы, в качестве ингибиторов mek, а также композиции, способы применения и способы их приготовления | |
| GEP20125621B (en) | 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor | |
| HRP20050191B1 (hr) | Novi derivati benzoimidazola korisni kao antiproliferativna sredstva | |
| RU2009135616A (ru) | НОВЫЕ АМИДАЗО[4,5-b]ПИРИДИН-7-КАРБОКСАМИДЫ 704 | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| JP2011515482A5 (https=) | ||
| NO20076195L (no) | Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer | |
| JP2014511892A5 (https=) | ||
| HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
| JP2014507455A5 (https=) | ||
| AR074341A1 (es) | Derivados heterociclicos de isoindol, inhibidores de proteinasas bace, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de patologias relacionadas a deficiencias cognitivas, tales como alzheimer. | |
| CA2441565A1 (en) | Bisarylamines as potassium channel openers | |
| RU2013128968A (ru) | Соединения, активные в отношении кальций-чувствительного рецептора | |
| JP2013542267A5 (https=) | ||
| GB2586113A (en) | MTORC modulators and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20141007 |